QIAGEN Launches careHPV Test in India to Expand Preventive Screening Against Cervical Cancer
Feb 26 14
Qiagen NV announced the commercial launch in India of its careHPV(TM) Test, the only molecular diagnostic for high-risk human papillomavirus (HPV) designed to screen women in settings with limited healthcare infrastructure, such as areas lacking electricity, water or laboratories. HPV is the primary cause of cervical cancer in women, so screening for the viral infection is a powerful strategy for prevention and early treatment of the deadly cancer. The careHPV Test was launched commercially in China in 2013 and has been used in several other countries, including as part of QIAGEN's corporate social responsibility effort, QIAGENcares. The careHPV Test for low-resource settings is highly complementary with QIAGEN's digene HC2 HPV Test, the world's most validated and sensitive diagnostic test for detection of high-risk HPV. The digene HC2 HPV Test is recognized as the "gold standard" in HPV screening and is widely used in developed countries and in large cities in emerging markets. About 72,000 women in India die of cervical cancer each year, more than one-fourth of the world's 270,000 annual deaths. In India, cervical cancer accounts for about 20% of all cancer-related deaths in women and is the number one cause of death in middle-aged Indian women. The careHPV Test already plays an important role in QIAGENcares, QIAGEN's collaborations with NGOs and governments in which it helps expand access to high-quality cervical cancer screening in resource-poor regions. For example, tests for cervical cancer have been conducted on women in El Salvador using the careHPV Tests since 2012. The test will also be used in other countries, including Vanuatu. Also as part of QIAGENcares, QIAGEN and the Chittaranjan National Cancer Institute (CNCI) started a five-year-program in 2010 to provide cervical cancer screening with the digene HC2 HPV Test to 50,000 women in rural West Bengal. Screening is facilitated through mobile field clinics. This project has screened more than 36,000 women to date and has detected 216 cases of High Grade Squamous Intra-epithelial Lesions (HSIL) and 52 cases of cervical cancers. Most of the cervical cancers were at early treatable stages, and more than 90% of these patients have been treated at CNCI. In addition, many doctors and community-based healthcare workers have been trained in HPV screening. This project is the first HPV based screening project in India, demonstrating program aspects and successful implementation with clear deliverables. Cervical cancer is the second most common cancer among women worldwide, and research has shown that 80% of new cases and deaths occur in developing countries, where awareness of the disease and access to preventive tests and medical treatment is low. In many low-resource areas, cervical cancer has eclipsed breast cancer as the primary cancer killer of women.
Qiagen Announces Launches for Innovative Next-Generation Sequencing Products to Generate Valuable Insights from Any Sample
Feb 12 14
Qiagen NV announced the launch plans of several novel products designed to significantly reduce the challenges of the most significant bottlenecks in next-generation sequencing (NGS): sample preparation and bioinformatics. The solutions will enable NGS users to generate more valuable insights from any sample. The new products add to QIAGEN's rapidly expanding portfolio of 'universal' solutions designed to run with any NGS platform, including QIAGEN's GeneReader platform, which is being prepared for launch in 2014. Several of QIAGEN's new NGS products will be introduced to genomics researchers this week at the 15th annual Advances in Genome Biology and Technology (AGBT) meeting in Marco Island, Florida. At the AGBT meeting, QIAGEN will present a luncheon seminar on Saturday, February 15, featuring leading scientists discussing their use of QIAGEN NGS sample technologies, GeneRead custom panels, and Ingenuity and CLC bioinformatics products to enhance their workflows. Improving Sample Access: Gaining access to adequate amounts of high-quality sample material often is a challenge to all NGS applications. As the industry's leader in innovative sample technologies for collection, stabilization, isolation, purification and storage of samples, QIAGEN has created several new products designed specifically to help NGS users deal with difficult-to-handle samples, including: GeneRead DNA FFPE Kit provides a streamlined, easy-to-use procedure for efficient purification of DNA from formalin-fixed, paraffin-embedded (FFPE) tissue sections. Formalin treatment and storage introduce cytosine deamination, which leads to DNA sequence changes and potentially wrong data interpretation. An enzymatic step in the procedure eliminates these molecules from further analysis and reduces those effects significantly. QIAGEN has already shown dramatic improvements of data quality in several studies and will be sharing further data. Additionally the new GeneRead kit enables an increase of DNA yield. The GeneRead DNA FFPE Kit is now available. REPLI-g WTA Single Cell Kit and REPLI-g(R)Cell WGA & WTA Kit enable transcriptomic NGS analysis from single cells and comparative genomic and transcriptomic analysis from the same small sample. Both kits expand the REPLI-g single cell kit portfolio, which can make single cells accessible to NGS analysis by amplifying either DNA or RNA from individual cells. Using QIAGEN's proprietary MDA with the new SensiPhi polymerase (1,000-fold higher accuracy than Taq polymerase), the amplified nucleic acids show comparable performance to the original molecules, which allows users to perform multiple experiments from a single cell reliably and reproducibly. The REPLI-G WTA Single Cell Kit and the REPLI-g Cell WGA & WTA Kit are now available. Exosome sample-preparation kits enable processing of nucleic acids from exosomes, tiny messenger packages in a biological communication system that transmits genetic instructions from cell to cell. The kits will combine QIAGEN's proven sample technologies with technology developed by Exosome Diagnostics Inc. that allows non-invasive detection of key gene mutations and gene expressions in blood, urine and cerebrospinal fluid without the need for a risky and burdensome surgical tissue biopsy. The first kits will be launched in the second quarter of 2014. Enhancing Variant Identification: QIAGEN also announced plans to launch a line of GeneRead DNAseq panels V2.0 in the second quarter of 2014. This second-generation line of products provides an easy-to-use, highly sensitive and specific PCR-based target enrichment approach compatible with any NGS platform. The 14 new gene panels target a broad range of relevant genetic variants for clinical research. The GeneRead DNAseq panel V2.0 provides the most extensive collection of wet-bench verified catalog gene panels, covering actionable cancer mutations, clinically-relevant tumor mutations, tissue-specific cancers, comprehensive cancer, cancer predisposition, comprehensive carrier testing, and cardiomyopathy. Researchers also can design customized panels to meet their specific needs. GeneRead DNAseq panels use as little as 10 ng of starting DNA material, generate small amplicons (150 bp), and enable preparation of NGS libraries ready for sequencing within one day, making these products an ideal approach for sequencing FFPE samples in clinical research with any NGS sequencer. The panels are further supported by launch of the GeneRead DNAseq V2 chemistry, which along with the panels offers enhanced NGS performance metrics in terms of uniformity and specificity. Demonstrating Bioinformatics Leadership: QIAGEN also announced important new additions to its leading position in the emerging market for bioinformatics solutions for analysis and interpretation of NGS data in clinical research. Building on its acquisitions of Ingenuity and CLC bio in 2013, QIAGEN is helping a broad range of NGS customers achieve valuable insights from their sequencing data. These NGS products are all part of QIAGEN's portfolio of universal solutions, compatible with any next-generation sequencer and adding value to any NGS workflow. QIAGEN also is developing the benchtop GeneReader NGS platform for clinical research applications. Combined with QIAGEN's other NGS products, it will provide the first seamless automated workflow from biological sample, through DNA preparation, enrichment, library preparation, sequencing, data analysis and interpretation, to deliver valuable insights into diseases. Commercialization is planned for 2014.
Qiagen NV Launches First SYGNIS QualiPhi®-Based Products
Feb 12 14
Qiagen NV launched the first two products of a series of kits based on SYGNIS' proprietary amplification technology QualiPhi® now renamed SensiPhi®. The two kits, REPLI-g WTA Single Cel Kit and REPLI- g Cel WGA & WTA Kit, are available now and will be commercialized globally through QIAGEN's established distribution channels. The product launches result from a global exclusive license agreement with QIAGEN signed in 2012.